Investors bring class action against Mayne Pharma (ASX:MYX)
Mayne Pharma (MYX) faces a class action over alleged failures to inform…
Mayne Pharma Group Limited (MYX:ASX)
34.0¢
-0.01 (-2.86%)
MCAP $617.6M
Last trade
16.10pm 19/10/2021
20mins delayed
Latest Announcements
19/10/2021MYXMayne Pharma Group Limited
19/10/2021MYXMayne Pharma Group Limited
778
MCap
07/10/2021MYXMayne Pharma Group Limited
05/10/2021MYXMayne Pharma Group Limited
398
MCap
04/10/2021MYXMayne Pharma Group Limited
1,172
MCap
04/10/2021MYXMayne Pharma Group Limited
3,392
MCap
29/09/2021MYXMayne Pharma Group Limited
27/09/2021MYXMayne Pharma Group Limited
Company Overview
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
